收藏切换
Advances in tumor-infiltrating lymphocyte therapy for ovarian cancer
收藏切换
Quan-min LIU1, 2, Ping HUANG1, 2, Jia-chen SHI1, 2, Lan WANG1, 2, Yi-fang DENG1, 2, *
Chinese Journal of New Drugs | 2026, 35(17) : 1836 - 1842
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(17): 1836-1842
Advances in tumor-infiltrating lymphocyte therapy for ovarian cancer
Full
Quan-min LIU1, 2, Ping HUANG1, 2, Jia-chen SHI1, 2, Lan WANG1, 2, Yi-fang DENG1, 2, *
Affiliations
  • 1The National Key Laboratory of Lead Drugability Research, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2Shanghai Biogenic Substance Drugability Evaluation Professional Technical Service Platform, Shanghai 200437, China
Published: 2026-09-15 doi: 10.20251/j.cnki.1003-3734.2026.17.007
Outline
收藏切换

Ovarian cancer (OVCA) is a gynecological malignancy that poses a serious threat to women's health and life. Despite significant advances in modern medicine and surgery in recent years, the five-year survival rates for patients with stages Ⅲ and Ⅳ OVCA are only 27% and 13%, respectively. Tumor-infiltrating lymphocytes (TILs) are a type of immune cell that infiltrate the tumor parenchyma or stroma. Compared to non-tumor-infiltrating lymphocytes, TILs exhibit a stronger ability for antitumor immune responses. TIL therapy is an innovative cell-based treatment in which the therapeutic preparation is derived from the selection and expansion of autologous TILs obtained from the patient's own tumor tissue, offering potent antitumor activity and low off-target toxicity. Studies have shown that extensive TIL infiltration is associated with improved prognosis in OVCA patients after clinical treatment, and early-phase clinical trials have also demonstrated the feasibility of TIL therapy for OVCA. This review focuses on key TILs within the ovarian tumor microenvironment, the clinical translation of TIL therapy, and the potential challenges and optimization strategies for its clinical application, aiming to provide a scientific reference for TIL-based treatment of OVCA.

ovarian cancer  /  immunotherapy  /  tumor-infiltrating lymphocytes  /  adoptive cell therapy  /  tumor microenvironment
刘铨民, 黄萍, 施嘉晨, 王兰, 邓轶方. 基于肿瘤浸润淋巴细胞治疗卵巢癌的研究进展. 中国新药杂志, 2026 , 35 (17) : 1836 -1842 . DOI: 10.20251/j.cnki.1003-3734.2026.17.007
Quan-min LIU, Ping HUANG, Jia-chen SHI, Lan WANG, Yi-fang DENG. Advances in tumor-infiltrating lymphocyte therapy for ovarian cancer[J]. Chinese Journal of New Drugs, 2026 , 35 (17) : 1836 -1842 . DOI: 10.20251/j.cnki.1003-3734.2026.17.007
Year 2026 volume 35 Issue 17
54
7
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.17.007
  • Online Date:2026-10-26
  • Published:2026-09-15
Article Data
Affiliations
History
  • Accepted:2025-10-14
Affiliations
    1The National Key Laboratory of Lead Drugability Research, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
    2Shanghai Biogenic Substance Drugability Evaluation Professional Technical Service Platform, Shanghai 200437, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.17.007
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT